Studies have reported that Roxadustat can also maintain Hb above the target value in the treatment of renal anemia in calcification defense dialysis patients with oral iron supplementation.[26] Therefore, through this retrospective study, we want to confirm that Roxadustat combined with ESAs can be used to treat hemodialysis patients with renal anemia accompanied by secondary hyperparathyroidism, which can avoid serious adverse reactions caused by intravenous iron supplementation. This evidence concerns the gene GSTM1 and secondary hyperparathyroidism.